MedPath

Study to Evaluate Effectiveness of a Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery

Conditions
Bariatric Surgery
Comorbidity
Obesity, Morbid
Interventions
Other: PnK® Method
Other: standard diet
Registration Number
NCT03530566
Lead Sponsor
Protein Supplies SL
Brief Summary

Prospective multicenter observational clinical study on a dietary regimen in obese patients scheduled for bariatric surgery.

Detailed Description

Study population: 25 patients with morbid obesity (BMI ≥ 40 kg / m2) or severe obesity (BMI 35 to 39.9 kg / m2) , with two or more comorbidities, scheduled for bariatric surgery within 3 months, and who will start treatment with the multidisciplinary weight loss program (PnK Method) based on diet, exercise and psychological support.

Patients will be followed-up for 3 months, with the following controls: pre-selection, baseline, month 1, month 2, month 3, and control when hospital discharge.

The treatment schedule in these patients will be as follows: a very low calorie ketogenic diet for at least 1 month or until losing 10% of the weight, and then, a low calorie diet with gradual reintroduction of natural foods for 2 months, until surgery.

The investigators will obtain retrospective data from 25 patients treated with the standard diet who met the same inclusion/exclusion criteria as the patients in this study and who similarly resemble in age, sex and BMI, for comparative analysis (control group).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Patients of both sexes, between 18 and 65 years old
  • Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities associated with obesity (type 2 diabetes mellitus, arterial hypertension, obstructive sleep apnea, obesity hypoventilation syndrome, chronic respiratory disease, metabolic syndrome, atrial fibrillation, heart failure, pulmonary hypertension, cardiomyopathy, history of thrombosis, renal failure).
  • Patients scheduled for bariatric surgery within 3 months ± 1 week.
  • Patients who, regardless of their inclusion in this study, will undergo treatment with the multidisciplinary slimming program in study or standard diet.
  • Patients who agree to participate and sign the Informed Consent
Exclusion Criteria
  • Pregnant or lactating women.
  • Patients with type 1 diabetes mellitus or on insulin therapy
  • Patients with eating disorders, alcoholism, and/or drug addiction.
  • Patients with any severe psychological disorder (eg schizophrenia, bipolar disorder).
  • Patients receiving dicumarinic anticoagulants (Sintrom®) or cortisone.
  • Patients with liver failure.
  • Patients with severe kidney failure (gfr <30).
  • Patients with hemopathies.
  • Patients with cancer.
  • Patients with cardiovascular or cerebrovascular disease (heart rate disorders, recent infarction [<6m], unstable angina, decompensated heart failure, recent stroke [<6m]).
  • Patients in acute attack of gout.
  • Patients with renal lithiasis verified by ultrasound.
  • Patients with cholelithiasis verified by ultrasound.
  • Patients with depression.
  • Patients with electrolyte imbalance, according to medical criteria.
  • Patients with orthostatic hypotension.
  • Patients with contraindications to surgery

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Pnk groupPnK® MethodPatients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, scheduled bariatric surgery within 3 months will be treated with PnK® Method
Control groupstandard dietPatients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, treated with standard diet 3 moths prior bariatric surgery
Primary Outcome Measures
NameTimeMethod
Body weight loss at 3 monthesfrom baseline to 3 monthes

Change in body weight from baseline to 3 monthes

Secondary Outcome Measures
NameTimeMethod
Change in blood glucose at 3 monthesfrom baseline to 3 monthes

Change in blood glucose level from baseline to 3 monthes

Change in blood glucose at 2 monthesfrom baseline to 2 monthes

Change in blood glucose level from baseline to 2 monthes

Change in blood glucose at 1 monthfrom baseline to 1 month

Change in blood glucose level from baseline to 1 month

Change in HbA1c at 3 monthesfrom baseline to 3 monthes

Change in HbA1c (Glycated hemoglobin) percentage from baseline to 3 monthes

Change in HbA1c at 2 monthesfrom baseline to 2 monthes

Change in HbA1c (Glycated hemoglobin) percentage from baseline to 2 monthes

Change in HbA1c at 1 monthfrom baseline to 1 month

Change in HbA1c (Glycated hemoglobin) percentage from baseline to 1 month

Change in total cholesterol level at 1 monthfrom baseline to 1 month

Change in blood total cholesterol level from baseline to 1 months

Body weight loss at 2 monthesfrom baseline to 2 monthes

Change in body weight from baseline to 2 monthes

Body weight loss at 1 monthfrom baseline to 1 month

Change in body weight from baseline to 1 month

Change in systolic blood pressure at 3 monthesfrom baseline to 3 monthes

Change in systolic blood pressure from baseline to 3 monthes

Change in diastolyc blood pressure at 2 monthesfrom baseline to 2 monthes

Change in diastolyc blood pressure from baseline to 2 monthes

Change in diastolic blood pressure at 3 monthesfrom baseline to 3 monthes

Change in diastolic blood pressure from baseline to 3 monthes

Change in systolic blood pressure at 2 monthesfrom baseline to 2 monthes

Change in systolic blood pressure from baseline to 2 monthes

Change in systolic blood pressure at 1 monthfrom baseline to 1 month

Change in systolic blood pressure from baseline to 1 month

Change in diastolic blood pressure at 1 monthfrom baseline to 1 month

Change in diastolic blood pressure from baseline to 1 month

Change in total cholesterol level at 3 monthesfrom baseline to 3 monthes

Change in blood total cholesterol level from baseline to 3 monthes

Change in total cholesterol level at 2 monthesfrom baseline to 2 monthes

Change in blood total cholesterol level from baseline to 2 monthes

Change in triglycerides level at 3 monthesfrom baseline to 3 monthes

Change in blood triglycerides level from baseline to 3 monthes

Change in triglycerides level at 2 monthesfrom baseline to 2 monthes

Change in blood triglycerides level from baseline to 2 monthes

Change in triglycerides level at 1 monthfrom baseline to 1 month

Change in blood triglycerides level from baseline to 1 month

Metabolic Control of type 2 Diabetes at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse metabolic control of type 2 Diabetes at 3 months regarding baseline

Clinical Control of Hypertriglyceridemia at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical control of Hypertriglyceridemia at 3 months regarding baseline

Improvement of Sleep Apnea Obstructive Syndrome at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of Sleep Apnea Obstructive Syndrome, regarding baseline.

Clinical Control of arterial hypertension at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical control of arterial hypertension at 3 months regarding baseline

Clinical Control of Hypercholesterolemia at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical control of Hypercholesterolemia at 3 months regarding baseline

Improvement of Chronic Respiratory Disease at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of Chronic Respiratory Disease, regarding baseline.

Improvement of Obesity hypoventilation syndrome at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of Obesity hypoventilation syndrome, regarding baseline.

Improvement of Metabolic syndrome at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of Percentage of patients with better, equal or worse clinical symptoms of Obesity hypoventilation syndrome, regarding baseline.

Improvement of Atrial fibrillation at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of Atrial fibrillation, regarding baseline.

Improvement of Cardiac insufficiency at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of Cardiac insufficiency, regarding baseline.

Improvement of Pulmonary hypertension at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of Pulmonary hypertension, regarding baseline.

Length of anesthesiaDuring bariatric surgery

Length (in minuts) of anesthesia during bariatric surgery

Number of patients with intraoperative complicationsDuring bariatric surgery

Number of patients with intraoperative complications occurring during bariatric surgery and within the postoperative 24 hours

Number of patients with postoperative complications after bariatric surgeryAfter bariatric surgery

Number of patients with postoperative complications occurring before hospital discharge

Number of total days of hospitalizationAfter bariatric surgery

Number of total days of hospitalization after bariatric surgery

Improvement of Cardiomyopathy at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of cardiomyopathy, regarding baseline.

Improvement of Renal insufficiency at 3 monthsfrom baseline to 3 monthes

Percentage of patients with better, equal or worse clinical symptoms of Renal insufficiency, regarding baseline.

Obesity Surgery Mortality Risk Score3 months

Obesity Surgery Mortality Risk Score at the preoperative visit

Length of surgeryDuring bariatric surgery

Length (in minuts) of bariatric surgery

Number of Participants With Adverse Events related to preoperative weight loss treatmentThrough 3 months of study

Number of Participants with Adverse Events as a Measure of Safety and Tolerability of standardized weight-loss programme (PnK® Method)

Number of weight loss treatment dropout ratefrom baseline to 3 monthes

Number of weight loss treatment dropout rate from baseline to 3 months

Number of patients who refuse bariatric surgery at 3 monthsfrom baseline to 3 monthes

Number of patients who refuse bariatric surgery from baseline to 3 months

© Copyright 2025. All Rights Reserved by MedPath